PET/CT引导下中度大分割胸部放疗在肺功能严重受损的淋巴结阳性非小细胞肺癌中的初步可行性报告
本回顾性分析纳入8例肺功能严重受损(FEV1≤1.0 L和/或DLCO-SB≤40%和/或长期氧疗)的ⅢA-C期淋巴结阳性非小细胞肺癌患者,接受基于18F-FDG-PET/CT与4D-CT计划的Hypo-IGRT,总剂量45 Gy/15次。中位随访29.4个月,未观察到≥2级放射性肺炎,肺功能参数无显著下降,结论认为该方案可用于经严格筛选并密切监测的患者。
要点
- 8例肺功能严重受损的ⅢA-C期NSCLC患者完成45 Gy/15次Hypo-IGRT,无≥2级放射性肺炎。
- 中位PFS 19个月、OS 34.3个月,6个月与1年OS率分别为100%与87.5%。
- 4例出现2级放射性食管炎,随访中肺功能参数未见显著下降。
核心结论
- 在肺功能严重受损的局部晚期淋巴结阳性NSCLC患者中,PET/CT引导的中度大分割胸部放疗可行,未观察到严重肺毒性和肺功能参数的显著下降。
研究设计与样本
- 回顾性分析,纳入8例高度筛选并密切监测、肺功能严重受损(FEV1≤1.0 L和/或DLCO-SB≤40%和/或长期氧疗)的ⅢA-C期淋巴结阳性NSCLC患者。
- 计划基于治疗体位的18F-FDG-PET/CT与4D-CT,Hypo-IGRT总剂量45 Gy(ICRU)分15次每日照射,并在严格图像引导下实施。
- 放疗前及放疗后3、6个月分析肺活量(VC)、FEV1与DLCO-SB。
主要发现
- 中位随访29.4个月,中位年龄64岁;COPD GOLD Ⅳ、Ⅲ、Ⅱ级分别为4、3、1例,5例(63%)接受长期氧疗。
- 中位PTV为226.9 cc(范围100.17-379.80 cc);中位PFS 19个月,中位OS 34.3个月。
- 6个月与1年OS率分别为100%与87.5%,6个月与12个月PFS率分别为87.5%与52.5%;3例出现局部失败。
- 初始中位VC 1.69 L/预测值64.8%(范围1.36-2.66 L/33-80%)、FEV1 1 L/预测值39.4%(范围0.78-1.26 L/28-60%)、DLCO-SB预测值33.3%(范围13.3-54%)。
- 放疗后3与6个月中位VC、FEV1、DLCO-SB分别为2.05 L/56.35%(范围1.34-2.33 L/47-81.5%)、1.08 L/47.5%(范围0.74-1.60 L/30.8-59.59%)、38.55%(范围24-68%)与1.64 L/66%(范围1.41-2.79/35.5-75.5%)、1.0 L/47%(范围0.65-1.28 L/24.5-54.10%)、31%(范围27-43%)。
关键数值与推荐
- 全肺平均剂量9.4 Gy(范围5.3-11.6 Gy),双肺V20为15%(范围6-19%);食管平均剂量12.76 Gy(范围2.1-26.7 Gy)。
- 无≥2级放射性肺炎病例,4例发生2级放射性食管炎。
临床怎么用
- 对局部晚期淋巴结阳性且肺功能严重受损的NSCLC患者,可在个体化筛选与密切监测下考虑PET/CT引导的中度大分割胸部放疗。
- 该方案目前正在一项正在进行的单中心前瞻性研究中评估。
局限性
- 回顾性分析,样本量仅8例,且为高度筛选患者,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine the feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation (Hypo-IGRT) in locally advanced node-positive non-small cell lung cancer patients with highly compromised pulmonary function. METHOD: Eight highly-selected and closely monitored patients with highly diminished pulmonary function (FEV1 ≤ 1.0 L and/or DLCO-SB ≤ 40% and/or on long-term oxygen therapy) were treated with Hypo-IGRT. Planning was based on 18F-FDG-PET/CT and 4D-CT in the treatment position. Hypo-IGRT was delivered to a total dose of 45 Gy (ICRU) in 15 daily fractions under strict image-guidance. Vital capacity (VC), forced expiratory volume in 1 s (FEV1), and single-breath diffusing capacity of the lung for CO (DLCO-SB) were analyzed prior to, 3 and 6 months after Hypo-IGRT. RESULT: Eight patients with stage IIIA-C NSCLC (8th TNM Ed.) completed Hypo-IGRT. The median follow-up was 29.4 months. The median age was 64 years. Four, three and one patient(s) presented with COPD GOLD IV, III and II, respectively and 5 patients (63%) were on long-term oxygen therapy. The median PTV was 226.9 cc (range: 100.17-379.80 cc). Median PFS and OS were 19 and 34.3 months. The 6 months and 1-year OS rates were 100, 87.5%, respectively. The 6- and 12- months PFS rates were 87.5 and 52.5%. Three patients developed local failure. Median initial VC, FEV1 and DLCO-SB was 1.69 L/64.8% predicted (range: 1.36-2.66 L/33-80%), 1 L/39.4% predicted (range:0.78-1.26 L/28-60% predicted) and 33.3% (range: 13.3-54%) predicted, respectively. Median values for VC, FEV1, DLCO-SB 3 and 6 months after Hypo-IGRT were 2.05 L/56.35% predicted (range: 1.34-2.33 L/47-81.5%), 1.08 L/47.5% predicted (range: 0.74-1.60 L/30.8-59.59%), 38.55% (range: 24-68%) and 1.64 L/66% predicted (range: 1.41-2.79/35.5-75.5%), 1.0 L/47% predicted (range: 0.65-1.28 L/24.5-54.10%), 31% (range: 27-43%), respectively. Mean lung dose was 9.4 Gy (range: 5.3-11.6 Gy) and V20 for both lungs was 15% (range: 6-19%). Mean esophageal dose was 12.76 Gy (range: 2.1-26.7 Gy). There was no case of grade 2 or higher radiation pneumonitis. Four patients developed grade 2 radiation esophagitis. CONCLUSION: Hypo-IGRT can be considered for individual and closely monitored patients with locally advanced node-positive NSCLC with highly compromised pulmonary function. No severe pulmonary toxicity and significant decline of pulmonary function parameters was observed in our cohort. Currently, this protocol is being assessed in an ongoing single-centre prospective study.
引用
- Eze C, Taugner J, Roengvoraphoj O, et al. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis. Radiat Oncol. 2019. PMID: 31484542. doi:10.1186/s13014-019-1304-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。